Covestor
PVLA icon

Covestor’s Palvella Therapeutics PVLA Stock Holding History

Covestor’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$0 Sell
2
-2
-50% -$297 ﹤0.01% 2938
2026
Q2 		$1K Buy
4
+3
+300% +$364 ﹤0.01% 2418
2026
Q1 		$0 Buy
+1
New +$104 ﹤0.01% 2878

Other funds holding PVLA

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return

Covestor's PVLA Position: Q3 2026 in Review

Covestor reduced its Palvella Therapeutics (PVLA) stake by 50% in Q3 2026, selling an estimated $297 and leaving 2 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2938.

Covestor first reported a position in PVLA in Q1 2026 and has held it in 3 quarters since. The position peaked at $1K in Q2 2026. 141 funds tracked by Wall St. Rank hold PVLA as of Q3 2026.

  • Covestor held 2 shares of Palvella Therapeutics worth $0 as of Q3 2026.
  • Covestor sold 2 Palvella Therapeutics shares in Q3 2026, an estimated $297.
  • Palvella Therapeutics made up ﹤0.01% of Covestor's portfolio in Q3 2026, its #2938 holding.
  • Covestor first reported a position in Palvella Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Covestor's Palvella Therapeutics position peaked at $1K in Q2 2026.
  • 141 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2026.

Based on Covestor's 13F filing for Q3 2026, filed 30 Oct 2026.